Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
In recent years, the interest in using messenger RNA (mRNA) as a therapeutic means to tackle different diseases has enormously increased. This holds true not only for numerous preclinical studies, but mRNA has also entered the clinic to fight cancer. The advantages of using mRNA compared to DNA were recognized very early on, e.g., the lack of risk for genomic integration, or the expression of the encoded protein in the cytoplasm without the need to cross the nuclear membrane. However, it was generally assumed that mRNA is just not stable enough to give rise to sufficient expression of the encoded protein. Yet, an initially small group of mRNA aficionados could demonstrate that the stability of mRNA and the efficiency, by which the encoded protein is translated, can be significantly increased by selecting the right set of cis‐acting structural elements (including the 5′‐cap, 5′‐ and 3′‐untranslated regions, poly(A)‐tail, and modified building blocks). In parallel, significant advances in RNA packaging and delivery have been made, extending the potential for this molecule. This paved the way for further work to prove mRNA as a promising therapeutic for multiple diseases. Here, we review the developments to optimize mRNA regarding stability, translational efficiency, and immune‐modulating properties to enhance its functionality and efficacy as a therapeutic. Furthermore, we summarize the current status of preclinical and clinical studies that use mRNA for cancer immunotherapy, for the expression of functional proteins as so‐called transcript (or protein) replacement therapy, as well as for induction of pluripotent stem cells. WIREs RNA 2015, 6:471–499. doi: 10.1002/wrna.1288 This article is categorized under: Translation > Translation Regulation RNA Turnover and Surveillance > Turnover/Surveillance Mechanisms RNA in Disease and Development > RNA in Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Argonaute2 is the catalytic engine of mammalian RNAi
Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J.-J., Hammond, S. M., Joshua-Tor, L., & Hannon, G. J. (2004) · Science · doi:10.1126/science.1102513 · Cited by 2,796
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
AU-rich elements: characterization and importance in mRNA degradation
Chen, C.-Y. A., & Shyu, A.-B. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89102-1 · Cited by 1,948
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Mayr, C., & Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.06.016 · Cited by 1,613
Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs
Krieg, P. A., & Melton, D. A. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.18.7057 · Cited by 1,533
The highways and byways of mRNA decay
Garneau, N. L., Wilusz, J., & Wilusz, C. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2104 · Cited by 1,294 · cited 1×
“(5) Another benefit of mRNA is its functionality in the cytoplasm without the need to travel to the nucleus resulting in protein translation almost immediately after the transfer.”
BackgroundAt least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells
Kozak, M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90418-9 · Cited by 1,182
mRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062
Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases
Geurts, A. M., Cost, G. J., Freyvert, Y., Zeitler, B., Miller, J. C., Choi, V. M., Jenkins, S. S., Wood, A., Cui, X., Meng, X., et al. (2009) · Science · doi:10.1126/science.1172447 · Cited by 934
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
Boczkowski, D., Nair, S. K., Snyder, D., & Gilboa, E. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.465 · Cited by 915
Cationic liposome-mediated RNA transfection.
Malone, R. W., Felgner, P. L., & Verma, I. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6077 · Cited by 911
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
The tumorigenicity of human embryonic and induced pluripotent stem cells
Ben-David, U., & Benvenisty, N. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3034 · Cited by 889
Wang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3545 · Cited by 837
Züst, R., Cervantes-Barragan, L., Habjan, M., Maier, R., Neuman, B. W., Ziebuhr, J., Szretter, K. J., Baker, S. C., Barchet, W., Diamond, M. S., et al. (2011) · Nature Immunology · doi:10.1038/ni.1979 · Cited by 811
Human iPSC-based modeling of late-onset disease via progerin-induced aging
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 741
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA
Liu, L., Botos, I., Wang, Y., Leonard, J. N., Shiloach, J., Segal, D. M., & Davies, D. R. (2008) · Science · doi:10.1126/science.1155406 · Cited by 733
Regulation of cytoplasmic mRNA decay
Schoenberg, D. R., & Maquat, L. E. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3160 · Cited by 656
Zangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2682 · Cited by 646
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625
Pelletier, J., & Sonenberg, N. (1985) · Cell · doi:10.1016/0092-8674(85)90200-4 · Cited by 610
Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA
Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillet, J., Lévy, J., & Meulien, P. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230749 · Cited by 473
Van Tendeloo, V. F. I., Ponsaerts, P., Lardon, F., Nijs, G., Lenjou, M., Van Broeckhoven, C., Van Bockstaele, D. R., & Berneman, Z. N. (2001) · Blood · doi:10.1182/blood.v98.1.49 · Cited by 468
Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 464
Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., Pawelec, G., Hoerr, I., Rammensee, H.-G., & Garbe, C. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a00068 · Cited by 378
Van Tendeloo, V. F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008051107 · Cited by 377
Su, Z., Dannull, J., Yang, B. K., Dahm, P., Coleman, D., Yancey, D., Sichi, S., Niedzwiecki, D., Boczkowski, D., Gilboa, E., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3798 · Cited by 359
Efficient generation of human iPSCs by a synthetic self-replicative RNA
Yoshioka, N., Gros, E., Li, H.-R., Kumar, S., Deacon, D. C., Maron, C., Muotri, A. R., Chi, N. C., Fu, X.-D., Yu, B. D., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.06.001 · Cited by 312
Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0699 · Cited by 309
In Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles
Su, X., Fricke, J., Kavanagh, D. G., & Irvine, D. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100390w · Cited by 287
High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation
Zhao, Y., Zheng, Z., Cohen, C. J., Gattinoni, L., Palmer, D. C., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.688 · Cited by 283
Karikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282
An mRNA Stability Complex Functions with Poly(A)-Binding Protein To Stabilize mRNA In Vitro
Wang, Z., Day, N., Trifillis, P., & Kiledjian, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.4552 · Cited by 262
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
Weide, B., Carralot, J.-P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, I., Rammensee, H.-G., Garbe, C., & Pascolo, S. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815ce501 · Cited by 261
mRNA as gene therapeutic: How to control protein expression
Tavernier, G., Andries, O., Demeester, J., Sanders, N. N., De Smedt, S. C., & Rejman, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.020 · Cited by 232
Poly(A) Tail Shortening by a Mammalian Poly(A)-specific 3′-Exoribonuclease
Körner, C. G., & Wahle, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10448 · Cited by 230
Kuhn, A. N., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J., Darzynkiewicz, E., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Gene Therapy · doi:10.1038/gt.2010.52 · Cited by 226
Self-citationA novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines
Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25181 · Cited by 223
5’-triphosphate-dependent activation of PKR by RNAs with short stem-loops
Nallagatla, S. R., Hwang, J., Toroney, R., Zheng, X., Cameron, C. E., & Bevilacqua, P. C. (2007) · Science · doi:10.1126/science.1147347 · Cited by 222
Probst, J., Weide, B., Scheel, B., Pichler, B. J., Hoerr, I., Rammensee, H.-G., & Pascolo, S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302964 · Cited by 206
Systematic discovery of structural elements governing stability of mammalian messenger RNAs
Goodarzi, H., Najafabadi, H. S., Oikonomou, P., Greco, T. M., Fish, L., Salavati, R., Cristea, I. M., & Tavazoie, S. (2012) · Nature · doi:10.1038/nature11013 · Cited by 187
Bogers, W. M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E. J., Davis, D., Ulmer, J. B., Brito, L. A., Cu, Y., Banerjee, K., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu522 · Cited by 181
Morse, M. A., Nair, S. K., Mosca, P. J., Hobeika, A. C., Clay, T. M., Deng, Y., Boczkowski, D., Proia, A., Neidzwiecki, D., Clavien#, P.-A., et al. (2003) · Cancer Investigation · doi:10.1081/cnv-120018224 · Cited by 177
Caruso, D. A., Orme, L. M., Neale, A. M., Radcliff, F. J., Amor, G. M., Maixner, W., Downie, P., Hassall, T. E., Tang, M. L. K., & Ashley, D. M. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000668 · Cited by 165
Feeder-Free Derivation of Human Induced Pluripotent Stem Cells with Messenger RNA
Warren, L., Ni, Y., Wang, J., & Guo, X. (2012) · Scientific Reports · doi:10.1038/srep00657 · Cited by 154
Vaccination with Messenger RNA (mRNA)
Pascolo, S. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-72167-3_11 · Cited by 126
Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism
Mays, L. E., Ammon-Treiber, S., Mothes, B., Alkhaled, M., Rottenberger, J., Müller-Hermelink, E. S., Grimm, M., Mezger, M., Beer-Hammer, S., von Stebut, E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65351 · Cited by 113
Wang, Z., & Kiledjian, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.17.6334-6341.2000 · Cited by 113
Caruso, D. A., Orme, L. M., Amor, G. M., Neale, A. M., Radcliff, F. J., Downie, P., Tang, M. L. K., & Ashley, D. M. (2005) · Cancer · doi:10.1002/cncr.20911 · Cited by 106
Yu, J., & Russell, J. E. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5879-5888.2001 · Cited by 90
Differential Inhibition of mRNA Degradation Pathways by Novel Cap Analogs
Grudzien, E., Kalek, M., Jemielity, J., Darzynkiewicz, E., & Rhoads, R. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509121200 · Cited by 90
Karikó, K., Kuo, A., & Barnathan, E. S. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300930 · Cited by 89
Potential role of phenotypic mutations in the evolution of protein expression and stability
Goldsmith, M., & Tawfik, D. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809506106 · Cited by 81
Vivinus, S., Baulande, S., van Zanten, M., Campbell, F., Topley, P., Ellis, J. H., Dessen, P., & Coste, H. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02064.x · Cited by 67
Messenger RNA‐based vaccines: progress, challenges, applications
Kramps, T., & Probst, J. (2013) · WIREs RNA · doi:10.1002/wrna.1189 · Cited by 50
Targeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger Transcription Factors
Lara, H., Wang, Y., Beltran, A. S., Juárez-Moreno, K., Yuan, X., Kato, S., Leisewitz, A. V., Cuello Fredes, M., Licea, A. F., Connolly, D. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.360768 · Cited by 42
mRNA vaccination as a safe approach for specific protection from type I allergy
Weiss, R., Scheiblhofer, S., Roesler, E., Weinberger, E., & Thalhamer, J. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.168 · Cited by 42
Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics
Kuhn, A. N., Diken, M., Kreiter, S., Vallazza, B., Türeci, Ö., & Sahin, U. (2011) · RNA Biology · doi:10.4161/rna.8.1.13767 · Cited by 39
Self-citationBax mRNA therapy using cationic liposomes for human malignant melanoma
Okumura, K., Nakase, M., Inui, M., Nakamura, S., Watanabe, Y., & Tagawa, T. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1214 · Cited by 31
In vivo protein expression from mRNA delivered into adult rat brain
Karikó, K., Keller, J. M., Harris, V. A., Langer, D. J., & Welsh, F. A. (2001) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(00)00355-1 · Cited by 24
Messenger RNA vaccination and B-cell responses in NSCLC patients.
Sebastian, M., von Boehmer, L., Zippelius, A., Mayer, F., Reck, M., Atanackovic, D., Thomas, M., Schneller, F., Stoehlmacher-Williams, J., Goekkurt, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2573 · Cited by 13
Research works printed but not linked: 238
- 10.1016/S0092-8674(00)81517-2 · DOI · Paper page
- 10.1128/MCB.7.9.3268 · DOI · Paper page
- 10.1016/j.cell.2009.01.042 · DOI · Paper page
- 10.1002/wrna.40 · DOI · Paper page
- 10.1128/MCB.24.12.5521-5533.2004 · DOI
- 10.1038/nsmb1016 · DOI · Paper page
- 10.1016/S0092-8674(01)00225-2 · DOI · Paper page
- 10.1016/S0021-9258(19)37166-2 · DOI · Paper page
- 10.1016/S1097-2765(00)80442-6 · DOI · Paper page
- 10.1074/jbc.M102270200 · DOI · Paper page
- 10.1093/emboj/21.6.1427 · DOI · Paper page
- Li Y, 2010, Regulation of mRNA decapping, WlREs RNA, 1, 253
- Ling SH, 2011, Structural and functional insights into eukaryotic mRNA decapping, WlREs RNA, 2, 193
- 10.1073/pnas.192445599 · DOI · Paper page
- 10.1038/nsmb.1984 · DOI · Paper page
- Nagarajan VK, 1829, XRN 5′‐‐>3′ exoribonucleases: structure, mechanisms and functions, Biochim Biophys Acta, 2013, 590
- 10.1038/nrm1964 · DOI · Paper page
- 10.4161/rna.8.1.14237 · DOI · Paper page
- 10.1093/emboj/cdf448 · DOI · Paper page
- Schoenberg DR, 2011, Mechanisms of endonuclease‐mediated mRNA decay, WlREs RNA, 2, 582
- 10.1038/nrg2290 · DOI
- Schweingruber C, 1829, Nonsense‐mediated mRNA decay—mechanisms of substrate mRNA recognition and degradation in mammalian cells, Biochim Biophys Acta, 2013, 612
- Martin SA, 1975, Modification of RNA by mRNA guanylyltransferase and mRNA (guanine‐7‐)methyltransferase from vaccinia virions, J Biol Chem, 250, 9330, 10.1016/S0021-9258(19)40647-9 · DOI · Paper page
- 10.1016/0076-6879(89)80090-4 · DOI
- Pasquinelli AE, 1995, Reverse 5' caps in RNAs made in vitro by phage RNA polymerases, RNA, 1, 957
- 10.1261/rna.5430403 · DOI · Paper page
- Kore AR, 2010, Synthesis and evaluation of 2'‐O‐allyl substituted dinucleotide cap analog for mRNA translation, Bioorg Med Chem, 18, 8061, 10.1016/j.bmc.2010.09.013 · doi:10.1016/j.bmc.2010.09.013
- Kore AR, 2007, Synthesis and application of 2'‐fluoro‐substituted cap analogs, Bioorg Med Chem Lett, 17, 5295, 10.1016/j.bmcl.2007.08.029 · doi:10.1016/j.bmcl.2007.08.029
- 10.1021/ja901655p · DOI · Paper page
- Kore AR, 2008, Synthesis and application of a new 2′,3′‐isopropylidene guanosine substituted cap analog, Bioorg Med Chem Lett, 18, 4828, 10.1016/j.bmcl.2008.07.075 · DOI
- 10.1021/ol0167715 · DOI · Paper page
- Stepinski J, 2001, Synthesis and properties of mRNAs containing the novel "anti‐reverse" cap analogs 7‐methyl(3'‐O‐methyl)GpppG and 7‐methyl (3'‐deoxy)GpppG, RNA, 7, 1486
- 10.1016/j.bbrc.2005.12.105 · DOI · Paper page
- 10.1261/rna.701307 · DOI · Paper page
- 10.1016/j.bmc.2005.12.045 · DOI
- 10.1016/j.bmc.2013.05.041 · DOI
- Kowalska J, 2008, The first examples of mRNA cap analogs bearing boranophosphate modification, Nucleic Acids Symp Ser (Oxf), 52, 289, 10.1093/nass/nrn146 · DOI
- 10.1016/j.bmc.2012.01.013 · DOI
- 10.1039/b911347a · DOI
- 10.1039/b9nj00644c · DOI · Paper page
- 10.1261/rna.2430711 · DOI
- 10.1016/j.bmcl.2013.05.001 · DOI
- Benteyn D, 2013, Characterization of CD8+ T‐cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC‐MEL), Biomed Res Int, 2013, 976383, 10.1155/2013/976383 · DOI · Paper page
- 10.1186/1479-5876-12-175 · DOI
- 10.1146/annurev.cellbio.14.1.399 · DOI · Paper page
- 10.1016/S0021-9258(18)54860-2 · DOI · Paper page
- Velden AW, 2001, Vector design for optimal protein expression, Biotechniques, 31
- 10.1128/MCB.01445-06 · DOI · Paper page
- 10.1016/j.gde.2011.03.002 · DOI · Paper page
- 10.1073/pnas.94.6.2410 · DOI · Paper page
- 10.1177/153537020322800409 · DOI · Paper page
- 10.1128/MCB.26.6.2419-2429.2006 · DOI
- 10.1186/1479-0556-3-6 · DOI · Paper page
- 10.4049/jimmunol.180.1.309 · DOI · Paper page
- 10.4049/jimmunol.164.10.5508 · DOI · Paper page
- 10.1016/j.bbrc.2010.02.150 · DOI · Paper page
- 10.1016/j.gene.2006.12.013 · DOI
- 10.1016/j.tig.2012.07.006 · DOI · Paper page
- 10.1038/nrg2899 · DOI · Paper page
- 10.1038/mt.2012.29 · DOI · Paper page
- 10.1371/journal.pone.0017596 · DOI · Paper page
- 10.1089/jir.2005.25.1 · DOI · Paper page
- 10.1186/gb-2005-6-9-r75 · DOI · Paper page
- 10.1371/journal.pone.0038864 · DOI
- 10.1038/sj.gt.3302874 · DOI
- 10.1007/s00262-008-0556-8 · DOI
- 10.1016/j.clim.2005.12.009 · DOI · Paper page
- 10.1097/01.cji.0000210385.48327.1e · DOI
- 10.1182/blood-2005-01-0339 · DOI · Paper page
- 10.1038/mtna.2013.54 · DOI · Paper page
- 10.1002/biot.201000332 · DOI · Paper page
- 10.1073/pnas.89.21.10380 · DOI · Paper page
- Martin G, 1998, Tailing and 3'‐end labeling of RNA with yeast poly(A) polymerase and various nucleotides, RNA, 4, 226
- Boczkowski D, 2000, Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells, Cancer Res, 60, 1028
- 10.1017/S1355838298980669 · DOI · Paper page
- Peng J, 2005, mRNA with a <20‐nt poly(A) tail imparted by the poly(A)‐limiting element is translated as efficiently in vivo as long poly(A) mRNA, RNA, 11, 1131, 10.1261/rna.2470905 · DOI · Paper page
- 10.1089/hum.2006.17.1027 · DOI · Paper page
- 10.1186/1471-2199-9-90 · DOI · Paper page
- 10.1016/j.cbpa.2006.10.001 · DOI · Paper page
- Aurup H, 1994, Translation of 2'‐modified mRNA in vitro and in vivo, Nucleic Acids Res, 22, 4963, 10.1093/nar/22.23.4963 · doi:10.1093/nar/22.23.4963
- 10.1002/asia.200800370 · DOI
- 10.1021/ja801389n · DOI
- 10.1021/bi962674l · DOI · Paper page
- 10.1093/nar/15.10.4145 · DOI
- 10.1016/S0076-6879(00)17006-5 · DOI
- 10.1002/1439-7633(20010302)2:3<212::AID-CBIC212>3.0.CO;2-R · DOI · Paper page
- 10.1021/bi000579d · DOI
- 10.1074/jbc.273.21.13170 · DOI
- 10.1093/nar/gkq638 · DOI
- 10.1261/rna.1862210 · DOI · Paper page
- 10.1261/rna.038117.113 · DOI
- 10.1038/nprot.2007.480 · DOI
- Anderson AC, 1996, HPLC purification of RNA for crystallography and NMR, RNA, 2, 110
- 10.1261/rna.528007 · DOI · Paper page
- 10.1006/abio.1999.4030 · doi:10.1006/abio.1999.4030
- 10.1016/j.jpba.2012.04.031 · doi:10.1016/j.jpba.2012.04.031
- 10.1002/elps.200600673 · DOI
- 10.1016/j.ab.2009.01.040 · doi:10.1016/j.ab.2009.01.040
- 10.1016/j.ijpharm.2010.01.019 · DOI · Paper page
- 10.1006/jsre.2002.6435 · DOI
- 10.1111/j.1365-2567.2008.02833.x · DOI
- 10.1089/hum.2008.068 · DOI · Paper page
- 10.1038/sj.leu.2403463 · DOI
- 10.1007/s10544-010-9440-3 · DOI
- 10.1038/cgt.2009.61 · DOI · Paper page
- 10.1016/j.jconrel.2006.06.024 · DOI · Paper page
- 10.1111/j.1476-5381.2009.00288.x · DOI · Paper page
- 10.3109/1061186X.2010.504262 · DOI · Paper page
- 10.1007/978-1-62703-260-5_16 · DOI · Paper page
- 10.1002/0471142301.ns0422s57 · DOI
- Galla M, 2013, Retrovirus‐based mRNA transfer for transient cell manipulation, Methods Mol Biol, 969, 139, 10.1007/978-1-62703-260-5_10 · DOI
- 10.3390/v1010013 · DOI · Paper page
- 10.1074/jbc.M110.183780 · DOI · Paper page
- 10.1093/nar/gkr384 · DOI
- 10.1016/j.molcel.2004.09.023 · DOI
- 10.1016/j.tibtech.2009.02.002 · DOI
- 10.1038/mt.2010.298 · DOI
- 10.1172/JCI0214364 · DOI · Paper page
- 10.1016/j.coi.2011.03.007 · DOI
- 10.1097/00000658-200204000-00013 · DOI · Paper page
- 10.1038/gt.2011.17 · DOI · Paper page
- 10.4161/rna.8.4.15394 · DOI · Paper page
- 10.1002/eji.200425656 · DOI · Paper page
- 10.1038/35047123 · DOI · Paper page
- 10.1126/science.1093620 · DOI · Paper page
- 10.1002/eji.200636617 · DOI · Paper page
- 10.4049/jimmunol.177.11.8164 · DOI · Paper page
- 10.1146/annurev.immunol.23.021704.115633 · DOI · Paper page
- 10.1038/nature04517 · DOI · Paper page
- Kariko K, 2007, Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development, Curr Opin Drug Discov Devel, 10, 523
- 10.1038/35099560 · DOI · Paper page
- 10.1128/JVI.00935-08 · DOI · Paper page
- 10.1038/nature06765 · DOI · Paper page
- 10.1038/nature04734 · DOI · Paper page
- 10.1084/jem.20080091 · DOI · Paper page
- 10.1016/S0968-0004(00)01580-2 · DOI · Paper page
- 10.1021/bi061531o · DOI
- 10.1038/nature09489 · DOI · Paper page
- 10.1038/nsmb.1863 · DOI · Paper page
- 10.1371/journal.ppat.1003663 · DOI · Paper page
- 10.1128/JVI.00883-13 · DOI
- 10.1080/14653240902960411 · DOI
- 10.1073/pnas.1008051107 · DOI · Paper page
- 10.1002/(SICI)1097-0215(19990702)82:1<121::AID-IJC20>3.0.CO;2-X · DOI · Paper page
- Lesterhuis WJ, 2010, Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients, Anticancer Res, 30, 5091
- Coosemans A, 2010, Immunological response after therapeutic vaccination with WT1 mRNA‐loaded dendritic cells in end‐stage endometrial carcinoma, Anticancer Res, 30, 3709
- 10.1007/s00262-013-1453-3 · DOI · Paper page
- Berneman ZN, 2014, Dendritic cell vaccination in malignant pleural mesothelioma: a phase I/II study, J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.7583 · DOI
- 10.1158/1078-0432.CCR-11-3368 · DOI · Paper page
- 10.1016/j.ajo.2014.07.014 · DOI
- 10.1158/1078-0432.CCR-08-2982 · DOI · Paper page
- 10.1172/JCI67544 · DOI
- 10.1038/sj.cgt.7700961 · DOI · Paper page
- Neyns B, 2012, Phase IB study on combined intradermal (ID) and intravenous (IV) administration of autologous mRNA electroporated dendritic cells (DC) as a single‐agent cellular immunotherapy or combined with ipilimumab, J Clin Oncol, 30, 10.1200/jco.2012.30.15_suppl.2507 · doi:10.1200/jco.2012.30.15_suppl.2507
- Neyns B, 2014, Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC‐MEL) in combination with ipilimumab in patients with pretreated advanced melanoma, J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.3014 · doi:10.1200/jco.2014.32.15_suppl.3014
- 10.1158/0008-5472.CAN-08-3920 · DOI
- 10.1007/s00262-011-1176-2 · DOI
- 10.1097/CJI.0b013e31821dcb31 · DOI · Paper page
- 10.1093/annonc/mdt245 · DOI · Paper page
- 10.1007/s00262-014-1642-8 · DOI
- 10.1007/s00262-013-1438-2 · DOI
- Imhof M, 2013, Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study, J Clin Oncol, 31, 10.1200/jco.2013.31.15_suppl.3052 · doi:10.1200/jco.2013.31.15_suppl.3052
- 10.1016/S1470-2045(07)70142-0 · DOI
- Coosemans A, 2013, Immunological response after WT1 mRNA‐loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma, Anticancer Res, 33, 3855
- 10.1007/s00262-011-0991-9 · DOI
- 10.1385/IJGC:32:1:1 · DOI
- 10.1038/sj.bjc.6602761 · DOI · Paper page
- Su Z, 2003, Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA‐transfected dendritic cells, Cancer Res, 63, 2127
- 10.1172/JCI25947 · DOI · Paper page
- Healey D, 2010, Immunomonitoring of a phase I/II study of AGS‐003, a dendritic cell immunotherapeutic, as first‐line treatment for metastatic renal cell carcinoma, J Clin Oncol, 28, 10.1200/jco.2010.28.15_suppl.e13006 · doi:10.1200/jco.2010.28.15_suppl.e13006
- Amin A, 2014, Long‐term survival in unfavorable‐risk mRCC patients treated with a combination of autologous immunotherapy (AGS‐003) plus sunitinib, J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.4524 · DOI
- Willemen Y, 2012, Open label phase I/II study of Wilms' tumor gene 1 (WT1) mRNA‐transfected autologous dendritic cell vaccination in patients with solid tumors, J Clin Oncol, 30, 10.1200/jco.2012.30.15_suppl.e13051 · doi:10.1200/jco.2012.30.15_suppl.e13051
- Coosemans A, 2013, Wilms' tumor gene 1 (WT1)‐‐loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial, Anticancer Res, 33, 5495
- 10.1186/1471-2407-14-748 · DOI · Paper page
- Kübler H, 2011, Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self‐adjuvanted mRNA, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.4535 · DOI · Paper page
- 10.1038/mt.2010.289 · DOI · Paper page
- 10.1158/2326-6066.CIR-13-0022 · DOI · Paper page
- 10.1158/0008-5472.CAN-11-3722 · DOI · Paper page
- 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-# · doi:10.1002/1521-4141(200001)30:1<1::aid-immu1>3.0.co;2-#
- 10.1016/j.clim.2011.10.010 · DOI
- 10.1016/j.clim.2009.09.009 · DOI · Paper page
- 10.1097/TP.0000000000000272 · DOI · Paper page
- 10.1097/QAD.0b013e32834f33e8 · DOI · Paper page
- 10.2174/156652311796150390 · DOI · Paper page
- 10.1038/nri841 · DOI · Paper page
- 10.2174/156652309789753338 · DOI
- 10.1038/nbt.2938 · DOI · Paper page
- 10.1158/2326-6066.CIR-14-0108 · DOI · Paper page
- 10.2174/156652310791111001 · doi:10.2174/156652310791111001
- Clay TM, 1999, Efficient transfer of a tumor antigen‐reactive TCR to human peripheral blood lymphocytes confers anti‐tumor reactivity, J Immunol, 163, 507, 10.4049/jimmunol.163.1.507 · DOI · Paper page
- 10.1038/ni1001-957 · DOI · Paper page
- 10.1182/blood-2009-03-211714 · DOI · Paper page
- 10.1038/mt.2010.272 · DOI · Paper page
- 10.1200/JCO.2010.32.2537 · DOI · Paper page
- 10.1126/scitranslmed.3002842 · DOI · Paper page
- 10.1182/blood-2007-12-128843 · DOI · Paper page
- 10.1016/j.tibtech.2011.04.009 · DOI · Paper page
- 10.1038/nri2635 · DOI · Paper page
- 10.1038/mt.2010.24 · DOI · Paper page
- 10.1007/s00262-005-0098-2 · DOI
200 of 238 shown
Cited by
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
The challenge and prospect of mRNA therapeutics landscape
Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417
Materials for non-viral intracellular delivery of messenger RNA therapeutics
Kauffman, K. J., Webber, M. J., & Anderson, D. G. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.032 · Cited by 395
Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365
“Another approach is to inject naked mRNA into lymph nodes (reviewed in Vallazza et al.3) for efficient macropinocytotic uptake by resident hDCs.4,5 A third option, which is in clinical testing, uses intravenously administered nanoparticle formulations targeting mRNA specifically into lymphoid organs for body-wide expr…”
BackgroundSelf-citation
Metadata
- Authors
- Vallazza, B., Petri, S., Poleganov, M. A., Eberle, F., Kuhn, A. N., & Sahin, U.
- Venue
- WIREs RNA
- Publisher
- Wiley
- Published
- 2015-06-09
- Volume
- 6
- Issue
- 5
- Pages
- 471-499
- ISSN
- 1757-7004 (ISSN-L)
- 1757-7012
- OpenAlex
- W1518058088
- Cited by
- 72
- References
- 71
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.